Spire Wealth Management’s Myriad Genetics MYGN Stock Holding History

Spire Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-190	Closed	-$4K	–	2369
2022 Q3	$4K	Hold	190	–	–	﹤0.01%	1806
2022 Q2	$3K	Buy	+190	New	+$3.94K	﹤0.01%	2280
2022 Q1	–	Sell	-1,740	Closed	-$48K	–	2747
2021 Q4	$48K	Buy	+1,740	New	+$50.4K	﹤0.01%	1758
2021 Q2	–	Sell	-1,950	Closed	-$59K	–	2830
2021 Q1	$59K	Buy	+1,950	New	+$55.3K	﹤0.01%	1642

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Spire Wealth Management's MYGN Position: Q4 2022 in Review

Spire Wealth Management sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 190 shares — an estimated $4K sold.

Spire Wealth Management first reported a position in MYGN in Q1 2021 and held it in 4 quarters. The position peaked at $59K in Q1 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

Spire Wealth Management reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
Spire Wealth Management sold 190 Myriad Genetics shares in Q4 2022, an estimated $4K.
Spire Wealth Management first reported a position in Myriad Genetics in Q1 2021 and held it in 4 quarters.
Spire Wealth Management's Myriad Genetics position peaked at $59K in Q1 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Spire Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.